- Home
- AQMS vs LPCN Comparison
AQMS vs LPCN Comparison
Compare AQMS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- LPCN
- Stock Information
- Founded
- AQMS 2014
- LPCN 1997
- Country
- AQMS United States
- LPCN United States
- Employees
- AQMS N/A
- LPCN N/A
- Industry
- AQMS Metal Fabrications
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- LPCN Health Care
- Exchange
- AQMS Nasdaq
- LPCN Nasdaq
- Market Cap
- AQMS 11.1M
- LPCN 16.1M
- IPO Year
- AQMS 2015
- LPCN N/A
- Fundamental
- Price
- AQMS $1.11
- LPCN $3.23
- Analyst Decision
- AQMS Strong Buy
- LPCN Strong Buy
- Analyst Count
- AQMS 3
- LPCN 1
- Target Price
- AQMS $21.00
- LPCN $10.00
- AVG Volume (30 Days)
- AQMS 85.9K
- LPCN 10.5K
- Earning Date
- AQMS 05-08-2025
- LPCN 05-08-2025
- Dividend Yield
- AQMS N/A
- LPCN N/A
- EPS Growth
- AQMS N/A
- LPCN N/A
- EPS
- AQMS N/A
- LPCN N/A
- Revenue
- AQMS N/A
- LPCN $3,674,834.00
- Revenue This Year
- AQMS N/A
- LPCN N/A
- Revenue Next Year
- AQMS $550.00
- LPCN N/A
- P/E Ratio
- AQMS N/A
- LPCN N/A
- Revenue Growth
- AQMS N/A
- LPCN N/A
- 52 Week Low
- AQMS $1.05
- LPCN $2.75
- 52 Week High
- AQMS $10.44
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- AQMS 28.32
- LPCN 49.14
- Support Level
- AQMS $1.05
- LPCN $3.12
- Resistance Level
- AQMS $1.37
- LPCN $3.60
- Average True Range (ATR)
- AQMS 0.11
- LPCN 0.25
- MACD
- AQMS -0.02
- LPCN 0.02
- Stochastic Oscillator
- AQMS 9.79
- LPCN 38.80
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.